GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used... A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer.
- Mechanism
- Curator reviewed
GEM-231 has also demonstrated potentiation of the effects of certain conventional cytotoxic chemotherapy drugs. Hybridon is conducting studies of the DNA methyltransferase gene and has identified specific sequences on mRNA as targets for chemically-modified antisense oligonucleotides.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- GEM-231 · HYBO165
Resolves to
What you can answer from here — as of June 12, 2020
Which drugs share a target with GEM-231, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account